News

May 13, 2021May 13, 2021

$10.7M NIH Grant to Fund Genetic Research in Alzheimer’s

News

A $10.7-million grant to investigate the genetic underpinnings of Alzheimer’s disease has been awarded to the University of Pittsburgh Graduate School of Public Health and Washington University School of Medicine ... Read more

May 10, 2021May 10, 2021

Insufficient Evidence of Aducanumab Efficacy, ICER Draft Report Finds

News

A draft report from the Institute for Clinical and Economic Review, known as ICER, found that there is insufficient evidence to determine whether the investigational therapy aducanumab will provide health ... Read more

May 6, 2021May 6, 2021

Longeveron’s Stem Cell Therapy Shows Potential in Phase 1 Trial

News

Longeveron’s Lomecel-B, an investigational bone marrow-derived medicinal signaling cell (MSC), showed an ability to slow cognitive decline and the loss of daily life abilities in patients with mild Alzheimer’s disease relative to those given ... Read more

May 3, 2021May 3, 2021

FDA Places Gene Therapy LX1001 on Fast Track

News

LX1001, a gene therapy for Alzheimer’s disease being developed by Lexeo Therapeutics, has been granted fast track designation by the U.S. Food and Drug Administration (FDA). The therapy is designed ... Read more

April 29, 2021April 29, 2021

#AANAM – Nuplazid Not Linked to Side Effects Common to Antipsychotics

News

Acadia Pharmaceuticals’ Nuplazid (pimavanserin) — which is being evaluated as a potential treatment for hallucinations and delusions associated with dementia-related psychosis — is not associated with common motor side effects ... Read more

April 26, 2021April 26, 2021

Movement Gets Youth Involved in Alzheimer’s Advocacy, Education

News

Alzheimer’s disease is not often seen among those younger than 65, but the Youth Movement Against Alzheimer’s is getting young people involved with the neurological disorder through volunteer work, education, ... Read more

April 23, 2021April 23, 2021

#AANAM – EMBARK Trial to Again Test Safety, Efficacy of Aducanumab

News

A new Phase 3 clinical trial, called EMBARK, will evaluate the long-term safety and efficacy of aducanumab (BIIB037), an investigational therapy for Alzheimer’s disease in patients who took part in its ... Read more

April 22, 2021April 23, 2021

#AANAM – Lecanemab Safely, Quickly Lowers Amyloid Clumps in Trial

News

Eisai and Biogen’s experimental therapy lecanemab (BAN2401) safely leads to rapid and sustained reductions in the brain levels of beta-amyloid — the protein that forms toxic clumps in Alzheimer’s — ... Read more

April 19, 2021April 19, 2021

Greater Support for Dementia Patients Needed Across Europe, Report Says

News

Despite minor improvements in recent years, the availability of care for people with dementia in Europe is largely inadequate, according to a new report. The report, “Dementia Monitor 2020,” was ... Read more

April 15, 2021April 15, 2021

Safety Seen in Trial of Oral Treatment, Anavex 2-73, for Early Alzheimer’s

News

Following a positive review of preliminary data, an independent board recommended the Phase 2b/3 study investigating oral Anavex 2-73 (blarcamesine) in people with early Alzheimer’s disease continue without modification. As specified in trial ... Read more